At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV, Open-label, Multicentre, International Trial of Response Guided Treatment With Directly Observed Pegylated Interferon Alfa 2b (PEG-IFN-alfa 2b) and Self Administered Ribavirin (RBV) for Patients With Chronic HCV Genotype 2 or 3 and Injection Drug Use
In Brief
A Phase 4 clinical trial evaluating Pegylated interferon alfa 2b and Ribavirin for Hepatitis C, Chronic. Completed, enrolled 93 participants across 17 sites in 7 countries.
Detailed Summary
This sudy will determine whether shortening treatment for hepatitis C is feasible, safe and effective for patients who are current injection drug users or receiving opiate substitution therapy and who are responding well to treatment early on.
Study Details
Timeline
Interventions
Pegylated interferon alfa 2b 1.5 mcg/kg/week to a maximum of 150 mcg/week administered subcutaneously once weekly directly observed.
Ribavirin - 800-1400 mg daily according to weight taken orally with food, self administered in split doses.